What We're Reading: Page 224
Industry reads hand-picked by our editors
Aug 26, 2019
-
STAT
They rallied around 'our boys' with Duchenne. Where did that leave girls?
-
The New York Times
The $6 Million Drug Claim
-
The Wall Street Journal
New Details Emerge Over Mallinckrodt’s Role in Opioid Crisis
Aug 23, 2019
-
MIT Technology Review
The next trick for CRISPR is gene-editing pain away
-
The New York Times
Life-Changing Drugs Almost Nobody Can Afford
-
The Wall Street Journal
Customers Handed Over Their DNA. The Company Let the FBI Take a Look.
Aug 22, 2019
-
Bloomberg
Health Investment Firm OrbiMed Growing Wary of a Tougher FDA
-
The Wall Street Journal
Time to Throw In the Towel on Biosimilars
-
BioCentury
Biomedical stakeholders caution against limiting U.S.-China collaboration
-
Washington Post
Gilead files challenge to government patents for HIV prevention pill
Aug 21, 2019
Aug 20, 2019
-
AP
Brand-name drug prices rising at slower pace, lower amounts
-
The Wall Street Journal
Two Drugmakers Closing In on Opioid Settlements
-
Reuters
Who is next in big pharma's merger spree?
Aug 19, 2019
-
The New York Times
A Nun, a Doctor and a Lawyer — and Deep Regret Over the Nation's Handling of Opioids
-
Reuters
Novartis executive sold shares before drug data manipulation made public
-
Regulatory Focus
EMA and FDA Historically Agree on Just About Every New Drug Approval, But Is That Slowly Changing?
Previous
